King Drug Co of Florence Inc v. Smithkline Beecham Corporation, No. 14-1243 (3d Cir. 2015)
Annotate this CaseThis opinion or order relates to an opinion or order originally issued on June 26, 2015.
Download PDF
UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT No. 14-1243 KING DRUG COMPANY OF FLORENCE, INC.; LOUISIANA WHOLESALE DRUG CO., INC., on behalf of itself and all others similarly situated, Appellants v. SMITHKLINE BEECHAM CORPORATION, doing business as GLAXOSMITHKLINE; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS _______________________ On Appeal from the United States District Court for the District of New Jersey D.C. Civil Action No. 2-12-cv-00995 District Judge: Honorable William H. Walls ______________ Before: AMBRO, SCIRICA, and ROTH, Circuit Judges ORDER AMENDING OPINION The Precedential Opinion which was filed on June 26, 2015 shall be amended with respect to footnote 27 which appears on page 37 of the opinion. The footnote as amended shall read in its entirety: 27. We do not believe that the no-AG agreement was in fact an "exclusive" license. However, since the issue of whether such agreement is an exclusive license is not necessary for our decision here, we will leave its determination for another day. This amendment does not alter the original filing date of the opinion and the Court’s judgment. By the Court, s/ Anthony J. Scirica Circuit Judge Date: September 23, 2015
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
